As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

Analysts raised concerns about potential delays in reimbursement and policy support affecting the Lenacapavir launch. Gilead Sciences is poised for significant growth opportunities with the ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) in Q1 CY2025, with sales flat year on year at $6.67 billion. The ...

Leading data and analytics company GlobalData’s report, Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast, ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...

Now, thanks to Tomas Cihlar’s and Wesley Sundquist’s contributions, the world is a step closer to preventing infections ...

Why it matters: Gilead's stable outlook amid two key uncertainties—potential pharmaceutical tariffs and the upcoming launch of lenacapavir for the prevention of HIV—was reassuring. Gilead has ...

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

And there are innovators, like Tomas Cihlar and Wesley Sundquist, who came up with Gilead’s lenacapavir, a new way to treat ...

March 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s ...